Disease · MONDO_0005277

migraine disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. migraine disorder. Diseases, record MONDO_0005277. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005277

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: migraine disorder; Open Targets
Open Targets ID: MONDO_0005277; Open Targets
Other names: Abdominal Migraine, Abdominal Migraines, Acute Confusional Migraine, Acute Confusional Migraines, Cervical Migraine Syndrome, Cervical Migraine Syndromes, Disorder, Migraine, Disorders, Migraine, Headache, Migraine, Headache, Sick, Headaches, Migraine, Headaches, Sick, Hemicrania Migraine, Hemicrania Migraines, Migraine Disorders, Migraine Headaches, Migraine Syndrome, Cervical, Migraine Syndromes, Cervical, Migraine Variant, Migraine Variants, Migraine, Abdominal, Migraine, Acute Confusional, Migraine, Hemicrania, Migraines, Migraines, Abdominal, Migraines, Acute Confusional, Migraines, Hemicrania, Sick Headache, Sick Headaches, Status Migrainosus, Variant, Migraine, Variants, Migraine, migraine, migraine headache; Open Targets
Disease Ontology: DOID:6364; Disease Ontology
MeSH: D008881; MeSH
NCI Thesaurus: C89715; NCI Thesaurus
Highest stage of its drugs: Approval, for 60 of its 166 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs166

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SUMATRIPTAN	CHEMBL128	Small molecule	Approval	ATC, DailyMed and TTD	58	43	43	Drugs and targets
RIMEGEPANT	CHEMBL2178422	Small molecule	Approval	ATC, EMA Human Drugs and TTD	33	30	30	Drugs and targets
ERENUMAB	CHEMBL3833329	Antibody	Approval	ATC, DailyMed, EMA Human Drugs and FDA	31	25	25	Drugs and targets
NAPROXEN SODIUM	CHEMBL1200806	Small molecule	Approval	DailyMed and TTD	26	22	22	Drugs and targets
RIZATRIPTAN	CHEMBL905	Small molecule	Approval	ATC and TTD	23	21	21	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Approval	DailyMed	24	17	17	Drugs and targets
UBROGEPANT	CHEMBL2364638	Small molecule	Approval	ATC, DailyMed, FDA and TTD	21	17	17	Drugs and targets
LASMIDITAN	CHEMBL3039520	Small molecule	Approval	ATC, EMA Human Drugs and TTD	18	15	15	Drugs and targets
GALCANEZUMAB	CHEMBL3707328	Antibody	Approval	ATC, DailyMed, EMA Human Drugs, FDA and PMDA	20	14	14	Drugs and targets
EPTINEZUMAB	CHEMBL3833320	Antibody	Approval	ATC, DailyMed, EMA Human Drugs, FDA and TTD	19	13	13	Drugs and targets

1 to 10 of 166

See all 166 drugs

Targets144

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR1D	5-hydroxytryptamine receptor 1D	18	Serotonin 1d (5-HT1d) receptor agonist	Approval	https://conductscience.org/library/genes/3352	Drugs and targets
HTR1B	5-hydroxytryptamine receptor 1B	14	Serotonin 1b (5-HT1b) receptor agonist	Approval	https://conductscience.org/library/genes/3351	Drugs and targets
PTGS2	Cyclooxygenase	14	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	12	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
CALCRL	Calcitonin gene-related peptide type 1 receptor	11	Calcitonin gene-related peptide type 1 receptor antagonist; Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist	Approval	https://conductscience.org/library/genes/10203	Drugs and targets
SCN4A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Approval	https://conductscience.org/library/genes/6329	Drugs and targets
HTR1F	5-hydroxytryptamine receptor 1F	6	Serotonin 1f (5-HT1f) receptor agonist	Approval	https://conductscience.org/library/genes/3355	Drugs and targets
SCN10A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets

1 to 10 of 144

See all 144 targets

Trials409

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01332500	Treximet ™ Pharmacy Budget Impact Model Database Validation Study		61,737	2011-04-11	Migraine Disorders	NAPROXEN, SUMATRIPTAN	Its record names the disease	ClinicalTrials.gov
NCT03266588	Open Label Safety Study in Acute Treatment of Migraine	Phase 2/3	3,019	2020-07-02	Migraine, With or Without Aura	RIMEGEPANT	Its record names the disease	ClinicalTrials.gov
NCT02605174	Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine	Phase 3	3,005	2018-07-30	Migraine With or Without Aura	LASMIDITAN	Its record names the disease	ClinicalTrials.gov
NCT02439320	Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:	Phase 3	2,231	2019-11-27	Acute Migraine	LASMIDITAN	Its record names the disease	ClinicalTrials.gov
NCT02565186	An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine	Phase 3	2,171	2020-08-25	Migraine Disorders	LASMIDITAN	Its record names the disease	ClinicalTrials.gov
NCT03872453	Acute Treatment Trial in Adult Subjects With Migraines	Phase 2/3	2,154	2022-10-13	Migraine	ZAVEGEPANT	Its record names the disease	ClinicalTrials.gov
NCT04571060	Randomized Trial in Adult Participants With Acute Migraines	Phase 3	1,978	2023-03-16	Migraine	ZAVEGEPANT	Its record names the disease	ClinicalTrials.gov
NCT01286207	Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)	Phase 3	1,959	2011-06-10	Migraine Disorders	RIZATRIPTAN	Its record names the disease	ClinicalTrials.gov
NCT00483704	Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)	Phase 3	1,935	2014-08-29	Migraines	TELCAGEPANT	Its record names the disease	ClinicalTrials.gov
NCT03461757	Trial in Adult Subjects With Acute Migraines	Phase 3	1,811	2020-03-27	Migraine, With or Without Aura	RIMEGEPANT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 409

See all 409 trials

Comparisons in its trials218

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lasmiditan 100mg vs Lasmiditan 200mg: Number of Participants With at Least 1 Treatment Emergent Adverse Event	447 of 991	545 of 1,039	2,030	NCT02565186	Trial comparisons
Lasmiditan 100mg vs Lasmiditan 200mg: deaths from any cause	0 of 991	0 of 1,039	2,030	NCT02565186	Trial comparisons
Lasmiditan 100mg vs Lasmiditan 200mg: serious adverse events	29 of 991	36 of 1,039	2,030	NCT02565186	Trial comparisons
STS101 5.2 mg vs STS101 Placebo: deaths from any cause	0 of 731	0 of 729	1,460	NCT04940390	Trial comparisons
STS101 5.2 mg vs STS101 Placebo: serious adverse events	3 of 731	0 of 729	1,460	NCT04940390	Trial comparisons
STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose	265 of 716	230 of 708	1,424	NCT04940390	Trial comparisons
STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose	146 of 716	124 of 708	1,424	NCT04940390	Trial comparisons
STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Relief From Migraine Headache Pain at 2 Hours Post Dose	379 of 716	316 of 708	1,424	NCT04940390	Trial comparisons
Rimegepant vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis	102 of 135	979 of 1,260	1,395	NCT06680206	Trial comparisons
Rimegepant vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis	36 of 135	334 of 1,260	1,395	NCT06680206	Trial comparisons

1 to 10 of 218

See all 218 comparisons in its trials

Papers from its trials340

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41608705	RESULT	1	PubMed
39344988	RESULT	2	PubMed
38109984	RESULT	1	PubMed
37210098	RESULT	2	PubMed
37073858	RESULT	1	PubMed
37042545	RESULT	2	PubMed
36946234	RESULT	1	PubMed
36668895	RESULT	1	PubMed
36268304	RESULT	1	PubMed
36054144	RESULT	1	PubMed

1 to 10 of 340

See all 340 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005277

GET https://conductscience.org/api/diseases/v1/MONDO_0005277/drugs?page=2

API reference For AI assistants